Easton Pharmaceuticals Inc.
PINK SHEETS : EAPH

September 13, 2011 11:49 ET

Easton Pharmaceuticals to Enter Into Clinical Safety Trials of VIORRA for North American Market

TORONTO, ONTARIO--(Marketwire - Sept. 13, 2011) - Easton Pharmaceuticals Inc (PINK SHEETS:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced today the company is in the process of formalizing a plan to enter into North American clinical trials of VIORRA as a precursor to future North American product launch.

Easton is formulating a strategy to undertake additional clinical trials, which involves entering into an estimated 6 month clinical trial program at various well established clinic(s) within North America. Easton's highly skilled team of doctors and consultants shall provide input into the scope and process including the various clinics being contemplated for the trials. The total scale and depth of the trials are dependant on various factors including sufficient capital to fully complete a well detailed trial and analysis on all possible safety issues prior to any marketing of the product in North America.

Any North American clinical safety trials do not necessarily imply Easton cannot proceed to the launch of VIORRA in various other markets outside of North America where such safety tests are not required prior to any marketing of the product including Mexico and other Latin American and East Asian markets. Such foreign markets possess their own internal requirements which are independent of any North American standards.

Easton Pharmaceuticals has previously undertaken various clinical trials of VIORRA and obtained positive efficacy results which has led the company to believe it would act as an effective over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity promoting a positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as (GRAS) Generally Recognized as Safe.

About Easton Pharmaceuticals Inc

Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.

The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit http://www.eastonpharma.com.

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.

Contact Information